Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Pharmaceuticals Holding Co's revenue per share for the
three
months ended in Jun. 2026 was $2.86.
Shanghai Pharmaceuticals Holding Co's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was $11.17.
During the past 12 months, the average Revenue Per Share Growth Rate of Shanghai Pharmaceuticals Holding Co was 4.20% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was 4.70% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 1.80% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 6.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
SHPMF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -15.4 Med: 12.7 Max: 141
Current: 4.7
During the past 13 years, Shanghai Pharmaceuticals Holding Co's highest 3-Year average Revenue Per Share Growth Rate was 141.00% per year. The lowest was -15.40% per year. And the median was 12.70% per year.
SHPMF's 3-Year Revenue Growth Rate is ranked better than 50% of 118
companies
in the Medical Distribution industry
Industry Median: 4.55
vs SHPMF: 4.70
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Shanghai Pharmaceuticals Holding Co Revenue per Share Related Terms
Shanghai Pharmaceuticals Holding Co Revenue per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co Revenue per Share Chart
SHPMF vs MCK, COR, CAH: Revenue per Share Comparison
For the Medical Distribution subindustry, Shanghai Pharmaceuticals Holding Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Pharmaceuticals Holding Co PS Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Shanghai Pharmaceuticals Holding Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Shanghai Pharmaceuticals Holding Co's PS Ratio falls into.
Shanghai Pharmaceuticals Holding Co Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Pharmaceuticals Holding Co (SHPMF) has a Revenue per Share of $11.17 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. According to the industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #59 out of 118 companies in the Medical Distribution industry, placing it in the top 50%.
Is Shanghai Pharmaceuticals Holding Co's Revenue per Share too high?
Shanghai Pharmaceuticals Holding Co's current Revenue per Share is $11.17. The Medical Distribution industry median Revenue per Share is 4.55. Shanghai Pharmaceuticals Holding Co's value of $11.17 is 145.5% above this industry median. Based on the distribution chart, Shanghai Pharmaceuticals Holding Co ranks #59 out of 118 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Shanghai Pharmaceuticals Holding Co has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Pharmaceuticals Holding Co's Revenue per Share compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Shanghai Pharmaceuticals Holding Co ranks #59 out of 118 companies for Revenue per Share. This puts Shanghai Pharmaceuticals Holding Co in the upper half of its industry. The industry median Revenue per Share is 4.55. Shanghai Pharmaceuticals Holding Co's value of $11.17 is 145.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Distribution company?
The median Revenue per Share among Medical Distribution companies is 4.55, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Pharmaceuticals Holding Co's current Revenue per Share of $11.17 is 145.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Shanghai Pharmaceuticals Holding Co and its competitors. For the Medical Distribution industry, the median Revenue per Share is 4.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Pharmaceuticals Holding Co's current Revenue per Share is $11.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Pharmaceuticals Holding Co stock overvalued right now?
Shanghai Pharmaceuticals Holding Co (SHPMF) has a current Revenue per Share of $11.17. The stock's GF Value™ is $1.78, compared to a current price of $1.46 — trading 18% below its estimated fair value. The current Revenue per Share is $11.17 and 145.5% above the Medical Distribution industry median of 4.55. Shanghai Pharmaceuticals Holding Co's overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Shanghai Pharmaceuticals Holding Co (SHPMF), the current Revenue per Share is $11.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Pharmaceuticals Holding Co (SHPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Pharmaceuticals Holding Co stock appears to be undervalued.
The current stock price of $1.46 is trading 18% below its estimated GF Value™ of $1.78.
Key valuation signals for SHPMF:
Revenue per Share: $11.17
GF Value™: $1.78 vs. price of $1.46 (18% below fair value)
Industry Position: 145.5% above the Medical Distribution median (#59 of 118)
No single metric tells the full story. See the SHPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Pharmaceuticals Holding Co Ltd is engaged in the pharmaceutical drug development and distribution business. The Group's reportable segments are: Production, Distribution, Retail, and Other. The majority of its revenue comes from the Distribution segment, which is mainly engaged in distribution, warehousing, and other value-added pharmaceutical supply chain solutions and related services for pharmaceutical manufacturers and dispensers. The Retail segment operates a network of retail pharmacy stores, and the Production segment is mainly engaged in research and development, production, and sales of a broad range of pharmaceutical and healthcare products. Geographically, the Group mainly operates in the People's Republic of China (PRC).
73GF Score
Get the complete analysis for SHPMF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHPMF has been successfully added to your 
